FANGDAPACKAGING
838163
Shandong Meichen Science & Technology
300237
HPF Co.,Ltd.
300350
4
Brilliance Technology
300542
5
Lakala Payment
300773
CN Stock MarketDetailed Quotes
301258 Suzhou Fushilai Pharmaceutical
- 29.09
- +4.85+20.01%
Market Closed Apr 22 15:00 CST
2.67BMarket Cap77.16P/E (TTM)
29.09High25.52Low102.99KlotVolume25.85Open24.24Pre Close282.98MTurnover30.41%Turnover Ratio162.51P/E (Static)91.67MShares42.7952wk High1.40P/B985.34MFloat Cap19.6352wk Low29.09Limit Up33.87MShs Float78.81Historical High19.39Limit Down14.73%Amplitude19.06Historical Low0.60Dividend TTM27.48Avg Price46.84KlotAsk2.07%Div YieldTTM100Lot Size51.67KlotBid
Suzhou Fushilai Pharmaceutical Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 17.44%113.08M | -12.23%429.47M | -19.59%312.49M | -27.14%216.64M | -38.47%96.29M | -13.89%489.29M | -2.35%388.63M | 9.17%297.35M | 10.38%156.49M | 8.92%568.21M |
| Operating revenue | 17.44%113.08M | -12.23%429.47M | -19.59%312.49M | -27.14%216.64M | -38.47%96.29M | -13.89%489.29M | -2.35%388.63M | 9.17%297.35M | 10.38%156.49M | 8.92%568.21M |
| Other operating revenue | ---- | -44.10%3.46M | ---- | -71.11%1.41M | ---- | -67.86%6.19M | ---- | -63.02%4.89M | ---- | 92.00%19.26M |
| Total operating cost | 18.80%110.68M | 9.51%426.1M | 8.71%313.8M | 4.10%210.46M | -11.56%93.17M | 5.89%389.09M | 12.02%288.66M | 14.84%202.17M | 2.67%105.35M | -4.75%367.44M |
| Operating cost | 25.52%92.8M | 14.53%345.17M | 10.65%248.44M | 4.28%168.43M | -11.93%73.94M | -3.15%301.38M | 0.84%224.54M | 8.46%161.52M | 4.21%83.95M | -0.11%311.18M |
| Operating tax surcharges | 31.93%1.23M | -25.85%4.01M | -36.14%2.91M | -36.66%2.14M | -44.37%933.72K | 6.13%5.41M | 24.12%4.55M | 17.38%3.38M | 8.18%1.68M | 24.12%5.1M |
| Operating expense | -40.25%639.31K | 7.53%5.26M | 3.72%3.83M | 18.99%2.75M | -6.86%1.07M | 10.10%4.89M | 9.98%3.69M | 12.27%2.31M | -2.55%1.15M | -5.47%4.44M |
| Administration expense | -3.71%8.49M | -10.16%41.32M | -7.61%30.76M | -9.06%20.61M | -12.19%8.82M | 6.46%46M | 5.37%33.29M | 5.31%22.66M | 3.27%10.05M | 31.98%43.2M |
| Financial expense | 51.52%-1.41M | -10.72%-10.29M | 42.98%-4.54M | 6.41%-6.43M | -315.57%-2.9M | 75.45%-9.29M | 77.13%-7.96M | 65.12%-6.88M | -184.23%-698.55K | -1,007.46%-37.86M |
| -Interest expense (Financial expense) | -26.09%18.6K | -21.93%90.91K | -21.24%70.64K | -20.59%48.72K | -19.97%25.17K | -62.09%116.46K | -64.30%89.69K | -75.58%61.35K | -82.27%31.45K | -31.74%307.22K |
| -Interest Income (Financial expense) | 37.60%-1.45M | 11.54%-7.17M | 9.01%-5.15M | -12.84%-4.35M | -41.31%-2.33M | -20.15%-8.11M | -31.99%-5.66M | -22.10%-3.85M | -141.59%-1.65M | -239.36%-6.75M |
| Research and development | -21.13%8.92M | -0.20%40.62M | 6.09%32.41M | 19.82%22.97M | 22.63%11.31M | -1.61%40.7M | -2.08%30.55M | -5.90%19.17M | 5.18%9.23M | 45.08%41.37M |
| Credit Impairment Loss | -705.48%-1.03M | -232.13%-1.55M | -167.10%-797.52K | -317.04%-1.1M | -115.41%-127.51K | 441.99%1.17M | 51.08%1.19M | 101.34%508.37K | 248.89%827.37K | 15.90%-342.52K |
| Asset Impairment Loss | 217.29%322.26K | -9,971.56%-15.82M | -775.28%-14.46M | -726.21%-13.5M | -36.76%-274.76K | 104.31%160.29K | 1.96%2.14M | 14.60%2.16M | ---200.9K | -36.15%-3.72M |
| Other net revenue | 712.39%25.5M | -49.57%16.85M | -30.21%18.2M | -142.00%-7.21M | -65.45%3.14M | 577.39%33.42M | 223.62%26.07M | 112.54%17.16M | 23.55%9.08M | -12.99%4.93M |
| Fair value change income | 413.70%16.2M | -263.22%-10.3M | 95.77%11.15M | -627.04%-5.32M | -300.50%-5.17M | 833.09%6.31M | 143.80%5.7M | 115.45%1.01M | 330.10%2.58M | -153.35%-860.99K |
| Invest income | 21.90%8.86M | 90.66%39.76M | 29.63%18.29M | -15.30%9.94M | 48.16%7.27M | 1,332.26%20.86M | 44.35%14.11M | 111.30%11.73M | 313.20%4.91M | -44.65%1.46M |
| Asset deal income | ---- | -136.68%-928.41K | ---101.86K | ---- | ---- | ---392.26K | ---- | ---- | ---- | ---- |
| Other revenue | -20.64%1.14M | 7.07%5.69M | 39.96%4.11M | 58.26%2.78M | 47.36%1.44M | -36.77%5.31M | -65.00%2.94M | -74.65%1.76M | -84.08%974.56K | 84.02%8.4M |
| Operating profit | 345.87%27.9M | -84.86%20.22M | -86.61%16.88M | -100.92%-1.03M | -89.61%6.26M | -35.04%133.62M | -15.04%126.04M | 7.60%112.34M | 29.48%60.23M | 45.25%205.71M |
| Add:Non operating Income | -43.96%1.3K | -24.90%35.6K | 122.74%4.38K | 354.90%3.46K | 329.63%2.32K | 4.29%47.4K | 80.29%1.97K | 55.12%760.11 | 38.46%540 | 2,033.81%45.45K |
| Less:Non operating expense | -90.60%26.31K | -60.03%2.05M | -22.68%1.71M | 12.38%779.77K | -37.01%280.06K | 55.51%5.12M | 19.16%2.21M | 5.02%693.87K | 142.29%444.6K | 3.56%3.3M |
| Total profit | 366.16%27.87M | -85.83%18.21M | -87.74%15.18M | -101.62%-1.81M | -90.00%5.98M | -36.51%128.54M | -15.48%123.83M | 7.62%111.65M | 29.03%59.79M | 46.24%202.46M |
| Less:Income tax cost | 1,943.26%3.94M | -88.96%1.81M | -92.01%1.33M | -109.54%-1.46M | -97.64%192.68K | -34.95%16.36M | -13.88%16.68M | 11.38%15.3M | 27.50%8.18M | 37.89%25.15M |
| Net profit | 313.65%23.94M | -85.38%16.41M | -87.08%13.84M | -100.36%-349.34K | -88.79%5.79M | -36.73%112.18M | -15.72%107.15M | 7.05%96.34M | 29.28%51.61M | 47.51%177.31M |
| Net profit from continuing operation | 313.65%23.94M | -85.38%16.41M | -87.08%13.84M | -100.36%-349.34K | -88.79%5.79M | -36.73%112.18M | -15.72%107.15M | 7.05%96.34M | 29.28%51.61M | 47.51%177.31M |
| Net profit of parent company owners | 313.65%23.94M | -85.38%16.41M | -87.08%13.84M | -100.36%-349.34K | -88.79%5.79M | -36.73%112.18M | -15.72%107.15M | 7.05%96.34M | 29.28%51.61M | 47.51%177.31M |
| Earning per share | ||||||||||
| Basic earning per share | 317.75%0.2636 | -85.25%0.18 | -87.08%0.151 | -100.36%-0.0038 | -88.79%0.0631 | -40.78%1.22 | -22.74%1.1689 | -6.34%1.051 | -2.93%0.563 | 17.71%2.06 |
| Diluted earning per share | 317.75%0.2636 | -85.25%0.18 | -87.08%0.151 | -100.36%-0.0038 | -88.79%0.0631 | -40.78%1.22 | -22.74%1.1689 | -6.34%1.051 | -2.93%0.563 | 17.71%2.06 |
| Other composite income | ||||||||||
| Total composite income | 313.65%23.94M | -85.38%16.41M | -87.08%13.84M | -100.36%-349.34K | -88.79%5.79M | -36.73%112.18M | -15.72%107.15M | 7.05%96.34M | 29.28%51.61M | 47.51%177.31M |
| Total composite income of parent company owners | 313.65%23.94M | -85.38%16.41M | -87.08%13.84M | -100.36%-349.34K | -88.79%5.79M | -36.73%112.18M | -15.72%107.15M | 7.05%96.34M | 29.28%51.61M | 47.51%177.31M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Rong Cheng Certified Public Accountants (Special General Partnership) | -- | -- | -- | Rong Cheng Certified Public Accountants (Special General Partnership) | -- | -- | -- | Rong Cheng Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.